{‘She lacks no qualifications’: the US medical field prepares for Høeg's role at the Food and Drug Administration.

As the United States continues making sweeping adjustments to its immunization guidelines, one figure has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning Covid shots throughout the global health crisis and has concentrated on alleged fatalities after Covid vaccination in her recent time at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Program

Health officials planned to reveal radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish national calendar, sources say – a major change that would put the US at odds with many the world with insufficient data for public health gain. This reveal has been postponed until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the center this calendar year.

A Shift at the Agency

This interim role may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood immunization guidelines in the US in order to be more similar to Denmark, a nation with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Background

The appointee has little discernible track record in medication creation, oversight or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past heads of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an immense portfolio at the agency, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office clears thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and each of these have to be supervised,” she explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the job, which supervises in excess of 5,000 staff members. “It’s a massive leadership role, if you do it right,” Woodcock added.

Response and Controversial Policies

When asked about questions about Høeg’s credentials and whether this appointment indicates increased cooperation among agency officials on vaccines, a representative stated that the “questions stem from inaccurate assumptions”.

“This background is consistent with the duties of her position,” the spokesperson stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day therapy clearance system that apparently worried her preceding directors. “By what process are these therapies being picked for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Overall, he said, “the FDA looks to be trending towards more relaxed rules of all drugs, with the exception of immunizations.”

Public History on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, past, critics observe. She released a analysis using unconfirmed volunteer-provided data to determine the rate of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming government encompassed altering rules for new vaccines and ending “non-essential” vaccines, she stated after the election on a audio program. At the FDA, Høeg has according to sources suggested preventing adolescent males from getting Covid vaccines.

“She’s an thorough true believer who commences with her beliefs and reverse-engineers to retrofit the data in a very misleading, fraudulent way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|